BACKGROUNDPrevious meta-analyses have systematically assessed the therapeutic effect of continuous blood purification (CBP) in adult patients with sepsis. Considering infection etiology and host response of sepsis is different in children, this systematic review and meta-analysis aims to evaluate the clinical efficacy of CBP in children with sepsis.METHODSStudies were searched from the Pubmed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang, and VIP databases. Outcomes included vital signs, coagulation markers, organ function markers, immune markers, inflammatory markers, and prognostic markers. Heterogeneity was evaluated by the I-square statistic (I²), and sensitivity analysis was performed.RESULTS24 studies were included in this meta-analysis. Pooled results showed that CBP decreased levels of alanine transaminase (ALT) (weighted mean difference [WMD] = -44.867, 95%CI: 64.809 to -24.926), aspartate aminotransferase (AST) (WMD = -55.373, 95%CI: 73.286 to -37.460), blood urea nitrogen (BUN) (WMD = -2.581, 95%CI: 4.539 to -0.622), and serum creatinine (Scr) (WMD = -11.567, 95%CI: 19.509 to -3.625). The percentage of CD3⁺ cells (WMD = 8.242, 95%CI: 3.339 to 13.144) and CD4⁺ cells (WMD = 4.278, 95%CI: 3.252 to 5.303, I² = 3.1 %) were increased in the CBP group. C-reaction protein (CRP) (WMD = -20.699, 95%CI: 34.740 to -6.657) and tumor necrosis factor-α (TNF-α) (WMD = -19.185, 95%CI: 34.133 to -4.237) were reduced after CBP treatment. Pediatric critical illness score (PCIS) was increased (WMD = 7.916, 95%CI: 4.317 to 11.516) and the risk of 28-day mortality (risk ratio [RR] = 0.781, 95%CI: 0.632 to 0.965) was lower in the CBP group.CONCLUSIONSCBP reduced the level of inflammatory markers, increased the level of immune markers, and improved organ function and prognosis, which may provide evidence for the use of CBP in sepsis children patients.

13 Nov 2024·ACS Applied Materials & Interfaces

Dual Emission and Low-Temperature Afterglow in Xanthone-Dibenzoazepine for High EQE Host–Guest OLEDs with Low-Efficiency Roll-Off

Article

Author: Bose, Sangita ; Agarwal, Neeraj ; Barhate, Komal Vasant ; Chanda, Pramya Ranjan ; Poojary, Mahesh

Research has been driven to demonstrate organic light-emitting diodes (OLEDs) with high efficiency, and in the quest for new materials, thermally activated delayed fluorescence (TADF) emitters have been employed. Preparation of donor-acceptor (D-A) π-conjugates is a useful guideline for developing TADF emitters. TADF emitters have shown excellent progress and high maximum external quantum efficiency (EQE_max) for OLEDs in the recent past; however, they suffer with substantial roll-off resulting in a decrease in their efficiency. In order to have efficient OLED emitters with less efficiency roll-off, we designed a xanthone-amine derivative with twisted electron-rich dibenzoazepine having limited rotation at the donor-acceptor bond. Xan-Azepine shows solvent polarity-dependent fluorescence in the range of 441- 597 nm having a lifetime below 10 ns. At 77 K in Me-THF, a triplet at 557 nm was observed having a decay lifetime of 0.75 s and an afterglow for about 6 s. In powder, it shows dual emission, i.e., fluorescence (490 and 6 ns) and phosphorescence (530 nm and 192 μs) at ambient conditions. The energy difference between the singlet and triplet energy levels of Xan-Azepine is found to be 0.18 eV in the powder sample. Its blend in 4,4'-bis(N-carbazolyl)-1,1'-biphenyl (CBP) showed delayed fluorescence with a lifetime of 118 μs at 300 K, while it reduced to 84 μs at 150 K. These observations suggest the TADF nature of Xan-Azepine in its CBP blend. OLED devices of Xan-Azepine showing a turn-on voltage of 2.8 V and a EQE_max of 12% were successfully fabricated. In the doped films of Xan-Azepine (5 wt %) with CBP, a maximum luminescence of 5980 Cd/m² at a current density of 70 mA/cm² was obtained, resulting in devices with low-efficiency roll-off (2.75%).

01 Sep 2024·Translational Cancer Research

Upregulation of miRNA-450b-5p targets ACTB to affect drug resistance and prognosis of ovarian cancer via the PI3K/Akt signaling pathway

Article

Author: Zhang, Jinyan ; Su, Yuting ; Xie, Shanzhou ; Yin, Fuqiang ; Liu, Xia

BackgroundOvarian cancer (OC) is the most malignant gynecologic cancer, and chemoresistance is a major cause of treatment failure in patients with OC. The understanding of microRNA (miRNA) in cancer is limited, and the role of miRNA (miR)-450b-5p in cancer drug resistance is unknown. In this study, we aim to evaluate the role of miR-450b-5p in drug-resistant OC and its underlying mechanisms.MethodsMiR-450b-5p expression was assessed in drug-sensitive and resistant OC cells via quantitative real-time polymerase chain reaction. Cell viability was evaluated using the Cell Counting Kit-8 assay. Progression-free survival (PFS) and overall survival (OS) curves were generated using the Kaplan-Meier method and the log-rank test. Target genes of miR-450b-5p were identified from the Cancer MIRNome database. Co-expressed genes were obtained from The Cancer Genome Atlas and Cancer Genome cBioportal for pathway enrichment and functional clustering analysis.ResultsThe miRNA-450b-5p expression was significantly increased in A2780 and SKOV3 OC-resistant cells and significantly increased by 17-fold in the A2780-CBP-Lv-miR-450b-5p cells compared to A2780-CBP and A2780-CBP-Lv-NC cells. The up-regulated expression of miR-450b-5p increased the cell viability and half maximal inhibitory concentration (IC₅₀) of A2780 platinum-resistant cells and was associated with poor OS. We obtained 33 potential target genes of miR-450b-5p and beta-actin (ACTB) might be a potential target of miR-450b-5p. Low expression of ACTB predicted poor OS and PFS. We obtained 362 common genes co-expressed with ACTB, which involved 4 critical pathways. PI3K acted as an upstream pathway of the other three pathways, which ultimately responded to drug resistance regulation in OC. The genes enriched in four pathways were cross-analyzed and 13 overlapping genes were obtained. These 13 genes were also significantly and positively co-expressed with ACTB at both protein and mRNA levels.ConclusionsHigh expression of miRNA-450b-5p might affect drug resistance and prognosis in OC by targeting 13 co-expressed genes of ACTB directly through the PI3K/Akt signaling pathway. Thus, miR-450b-5p might provide a new therapeutic target for drug resistance in OC.

100 Deals associated with Selective CBP(Foghorn Therapeutics)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Preclinical	US	Foghorn Therapeutics, Inc.	13 Jun 2024
Stomach Cancer	Preclinical	US	Foghorn Therapeutics, Inc.	13 Jun 2024
Bladder Cancer	Discovery	US	Foghorn Therapeutics, Inc.	17 Apr 2024
Colorectal Cancer	Discovery	US	Foghorn Therapeutics, Inc.	17 Apr 2024
Diffuse Large B-Cell Lymphoma	Discovery	US	Foghorn Therapeutics, Inc.	17 Apr 2024
Endometrial Carcinoma	Discovery	US	Foghorn Therapeutics, Inc.	17 Apr 2024
Non-Small Cell Lung Cancer	Discovery	US	Foghorn Therapeutics, Inc.	17 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Selective CBP(Foghorn Therapeutics)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation